Ipso Ventures Share Discussion Threads

[rgolding1978] 15/9/2011 14:34

careful newbies, dont get suckered in, this will be illiquid in no time and you wont be able to sell your shares you bought at over priced prices.

[falia] 15/9/2011 14:34

AND MKT CAP ONLY 1M

[james t kirk] 15/9/2011 14:34

How much is the payment they're referring to?

[falia] 15/9/2011 14:33

EVERY REASON TO SHOUT ON NEWS LIKE THIS LOLOL

[falia] 15/9/2011 14:33

EVERY REASON TO SHOUT ON NEWS LIKE THIS LOLOL

[dicko80] 15/9/2011 14:32

no need to shout !

[tomboyb] 15/9/2011 14:32

1.1 mill cap at these levels and NO DEBT.

[falia] 15/9/2011 14:32

LOOK AT THE MMS 1P GAP TO SCARE THE BUYERSAWAY LOLOL

[falia] 15/9/2011 14:32

LOOK AT THE MMS 1P GAP TO SCARE THE BUYERSAWAY LOLOL

[falia] 15/9/2011 14:30

NOW ITS APPROVED HAS TO BE A LOT MORE

[falia] 15/9/2011 14:30

IT WAS 5P WHEN THE ANNOUNCED TESTING

[falia] 15/9/2011 14:29

FLYING NOW

[topinfo] 15/9/2011 14:27

lol. This could hit 5p easily then,

[moreforus] 15/9/2011 14:23

only wins on the offer

10k FoK time!

[falia] 15/9/2011 14:22

LETTING YOU BUY NOTHING

[falia] 15/9/2011 14:20

MMS GIVING YOU 2.75P LOLOL

[moreforus] 15/9/2011 14:17

This approval has triggered a further milestone payment for Therakind. Therakind is expected to also receive royalties on sales of this product as Viropharma is now able to actively market this product across Europe.

IPSO has a 36% shareholding in Therakind.

[topinfo] 15/9/2011 14:16

Told yas!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!

[topinfo] 15/9/2011 14:15

DJ Ipso Ventures PLC EU grants approval for Buccolam

TIDMIPS

RNS Number : 3211O

Ipso Ventures PLC

15 September 2011

RNS ANNOUNCEMENT

For immediate release 15 September 2011

THERAKIND PRODUCT UPDATE

EU grants approval for Buccolam(R)

IPSO Ventures plc ("IPSO"), the creator of commercial value from technology, is pleased to report that further to the announcement on 1st July 2011 regarding Therakind, IPSO's portfolio company, and Buccolam(R) the European Commission has now granted approval for Buccolam(R) for the treatment of prolonged, acute, convulsive seizures in infants, toddlers, children and adolescents from 3 months to less than 18 years.

This approval has triggered a further milestone payment for Therakind. Therakind is expected to also receive royalties on sales of this product as Viropharma is now able to actively market this product across Europe.

IPSO has a 36% shareholding in Therakind.

Further information, please contact:

IPSO Ventures plc Tel: [phone]
Nick Rodgers, Chief Executive [e-mail]
Officer www.ipsoventures.com
Allenby Capital Limited Tel: [phone]
(Nominated adviser and broker)

[topinfo] 15/9/2011 13:53

Nice then.

[falia] 15/9/2011 13:52

second half of the year, value to the company and that statement was made when the share price was 10p+

[moreforus] 15/9/2011 13:50

falia

its on plus at 8.38am

[falia] 15/9/2011 13:50

Simon Hunt, Chairman of IPSO, said: "The last six months have not been easy for IPSO, but we believe that we have added value to our portfolio and we remain confident that we can realise some of that value in the second half of the year